Abstract
Gastrointestinal stromal tumors (GIST) are a unique class of mesenchymal tumors identified within the past decade. Intense molecular and genetic study has been used to characterize these tumors and develop treatment strategies. Although the mainstay of treatment remains surgical resection, therapy targeted at inhibiting tyrosine kinases has had dramatic results. Because of the rapid accumulation of information about the diagnosis and treatment of these tumors, the National Comprehensive Cancer Network convened a GIST task force to provide updated recommendations in 2010. As understanding of these tumors advances, rapid changes in recommendations will continue and should warrant regular updates in tumor management.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1079-1087 |
| Number of pages | 9 |
| Journal | Surgical Clinics of North America |
| Volume | 91 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- GIST
- Gastrointestinal stromal tumor
- Imatinib mesylate
- KIT
- PDGFRA
Fingerprint
Dive into the research topics of 'Gastrointestinal stromal tumor surgery and adjuvant therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS